IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT05173896 (ETLAS2) pour Maladies des petits vaisseaux cérébraux, AVC ischémique est actif, pas en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial (ETLAS2)
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'essai clinique NCT05173896 (ETLAS2) est conçu pour étudier la prevention de Maladies des petits vaisseaux cérébraux, AVC ischémique. Il s'agit d'un essai interventionnel en Phase II. Son statut actuel est : actif, pas en recrutement. L'essai a débuté le 31 mai 2022 et vise à recruter 100 participants. Dirigé par Christina Kruuse, l'essai devrait être terminé d'ici le 1 décembre 2029. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 9 décembre 2024.
Résumé succinct
In a randomized controlled trial the feasibility and effect of three months treatment with daily tadalafil, on cerebral blood flow/reactivity and cognition, is investigated in patients with cerebral small vessel disease.
Description détaillée
Cerebral small vessel disease is a progressive brain and blood vessel disease for which there currently is no effective treatment. The disease associates with 25 % of all stroke and 30 % of all dementia cases and imposes a major and increasing health burden worldwide. In this trial the investigator suggest a new promising solution to this problem.
Patients with cerebral small vessel disease, who experience stroke or vascular dementia, may show reduced brain perfusion or altered neurovascular reactivity. The investigator has previously shown that a single dose of tadalafil (20 mg), shortly increased blood supply to the brain in patients with cerebral small vessel disease. This holds promise for new effective treatment targets. The investigator test if patients find three months daily intake of tadalafil (20 mg) feasible, and if it alters cerebral perfusion, neurovascular reactivity, and cognition, including memory and planning ability. The trial will help identify new treatment targets to reduce the number of patients with stroke, stroke sequelae, and vascular dementia.
This trial is divided into one main study and three sub studies:
- Main study
- Dynamical MRI sub study
- Cognitive sub study
- Biomarker sub study
Titre officiel
Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
Conditions
Maladies des petits vaisseaux cérébrauxAVC ischémiquePublications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:- Olmestig J, Mortensen KN, Thomas MB, Fagerlund B, Robbins TW, Naveed N, Nordling MM, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Cognitive outcomes after tadalafil treatment in patients with cerebral small vessel disease: ETLAS-2 sub-study. Cereb Circ Cogn Behav. 2025 Nov 11;9:100520. doi: 10.1016/j.cccb.2025.100520. eCollection 2025.
- Olmestig J, Mortensen KN, Thomas MB, Fagerlund B, Naveed N, Nordling MM, Nielsen MKK, Rasmussen BS, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke. 2025 Oct;56(10):2846-2857. doi: 10.1161/STROKEAHA.125.051602. Epub 2025 Jul 28.
- Olmestig J, Mortensen KN, Fagerlund B, Naveed N, Nordling MM, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Cerebral blood flow and cognition after 3 months tadalafil treatment in small vessel disease (ETLAS-2): study protocol for a randomized controlled trial. Trials. 2024 Aug 29;25(1):570. doi: 10.1186/s13063-024-08402-4.
Autres identifiants de l'essai
- ETLAS2
- H-20031301
- 2020-002329-27 (Numéro EudraCT)
Numéro NCT
Date de début (réel)
2022-05-31
Dernière mise à jour publiée
2024-12-09
Date de fin (estimée)
2029-12
Inscription (estimée)
100
Type d'essai
Interventionnel
PHASE
Phase II
Statut
Actif, pas en recrutement
Objectif principal
Prévention
Plan d'attribution
Randomisé
Modèle d'intervention
Parallèle
Masquage
Quadruple aveugle
Bras / Interventions
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
ExpérimentalTadalafil Oral tadalafil (20 mg) capsules once daily for three months. | Tadalafil 20 MG Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months. |
Comparateur placeboPlacebo Oral placebo capsules once daily for three months. | PLACEBO Daily dose of oral over-encapsulated placebo tablets for three months. |
Critère principal d'évaluation
Critère secondaire d'évaluation
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Feasibility of treatment defined as proportion of participants achieving full target dose of tadalafil/placebo. | Number of participants achieving full target dose of tadalafil/placebo by end of three months trial period. Outcome will be assessed by a structured questionnaire with tablet count. | From baseline to three months. |
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
MRI - Cerebral Blood Flow | Change in cerebral blood flow measured with arterial spin labeling (ASL) during a sensory hand stimulus. | From baseline to three months. |
MRI - Neurovascular reactivity and perfusion | Change in neurovascular reactivity, coupling, and cerebral blood flow/perfusion measured with BOLD/ASL during a visual stimulation with and without a carbon dioxide vascular challenge. | From baseline to three months. |
MRI - Neurovascular reactivity | Change in neurovascular reactivity measured with blood-oxygen-level dependent (BOLD) during a sensory hand stimulus. | From baseline to three months. |
MRI - Blood Brain Barrier | Change in blood brain barrier measured with diffusion-prepared (DP)-ASL MRI. | From baseline to three months. |
MRI - STRIVE criteria | Relative changes (%) in STRIVE assessment, including new strokes, white matter hyperintensity, cerebral microbleeds, enlarged perivascular space, atrophy, and lacunes. | From baseline to three months. |
Montreal Cognitive Assessment | Change in Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome. | From baseline to three months. |
Symbol Digit Modalities Test | Change in Symbol Digit Modalities Test (SDMT) score. Score range 0-110. Higher scores mean a better outcome. | From baseline to three months. |
Dementia Assessment by Rapid Test | Change in Dementia Assessment by Rapid Test - DART score. Score range 0-50. Higher scores mean a better outcome. | From baseline to three months. |
Trail Making Test A | Change in time to perform Trail Making Test A. Quicker time means a better outcome. | From baseline to three months. |
Trail Making Test B | Change in time to perform Trail Making Test B. Quicker time means a better outcome. | From baseline to three months. |
Digit Span Forward | Change Digit Span Forward test score. Score range 0-16. Higher scores mean a better outcome. | From baseline to three months. |
Digit Span Backward | Change Digit Span Backward test score. Score range 0-16. Higher scores mean a better outcome. | From baseline to three months. |
Digit Span Arrangement | Change Digit Span Arrangement test score. Score range 0-16. Higher scores mean a better outcome. | From baseline to three months. |
WAIS Letter Number Sequence | Change Letter Number sequence test score. Score range 0-30. Higher scores mean a better outcome. | From baseline to three months. |
Word mobilising test - F, S, A, and animals | Change word mobilising test score. Higher scores mean a better outcome. | From baseline to three months. |
Cambridge Neuropsychological Test Automated Battery - Spatial Working Memory | Change in spatial working memory score. | From baseline to three months. |
Cambridge Neuropsychological Test Automated Battery - Motor Screening | Change in motor screening score. | From baseline to three months. |
Cambridge Neuropsychological Test Automated Battery - Rapid Visual Information processing | Change in rapid visual information processing score. | From baseline to three months. |
Cambridge Neuropsychological Test Automated Battery - Paired Associates Learning Task | Change in paired associates learning task score. | From baseline to three months. |
Cambridge Neuropsychological Test Automated Battery - One-Touch Stockings of Cambridge | Change in One-Touch Stockings of Cambridge score. | From baseline to three months. |
Cambridge Neuropsychological Test Automated Battery - Reaction Time | Change in reaction time score. | From baseline to three months. |
Short Informant Questionnaire on Cognitive Decline in the Elderly - IQCODE | Change in short IQCODE score. Score range 1-5. A score of 3 means that the subject is rated on average as 'no change'. | From baseline to three months. |
Becks Depression Inventory - BDD | Change in BDD score. Score range 0-63. Higher score means increased risk of depression. | From baseline to three months. |
Fatigue Severity Scale - FSS | Change in FSS score. Score range 0-7. Higher score means increased fatigue severity. | From baseline to three months. |
WHO-5 Well-Beeing Index | Change in WHO-5 score. Score range 0-100. Higher score means better quality of life. | From baseline to three months. |
Vascular- and inflammatory biomarkers: vascular cell adhesion molecule (VCAM-1) | Changes in vascular cell adhesion molecule (VCAM-1) (unit pg/ml). | From baseline to three months. |
Vascular- and inflammatory biomarkers: intercellular adhesion molecule-1 (ICAM-1) | Changes in intercellular adhesion molecule-1 (ICAM-1) (unit pg/ml). | From baseline to three months. |
Vascular- and inflammatory biomarkers: interleukin-6 (IL-6) | Changes in interleukin-6 (IL-6) (unit pg/ml). | From baseline to three months. |
Vascular- and inflammatory biomarkers: tumour necrosis factor alpha (TNF-α) | Changes in tumour necrosis factor alpha (TNF-α) (unit pg/ml). | From baseline to three months. |
Vascular- and inflammatory biomarkers: interleukin 1beta (IL-1β) | Changes in interleukin 1beta (IL-1β) (unit pg/ml). | From baseline to three months. |
Vascular- and inflammatory biomarkers: E-selectin | Changes in E-selectin (unit pg/ml). | From baseline to three months. |
Vascular- and inflammatory biomarkers: vascular endothelial growth factor (VEGF) | Changes in vascular endothelial growth factor (VEGF) (unit pg/ml). | From baseline to three months. |
Vascular- and inflammatory biomarkers: specific micro RNA | Changes in specific micro RNA associated to vascular disease. | From baseline to three months. |
Death, ischemic and hemorrhagic event, and dementia | Difference in composite measure of death, any ischemic event, hemorrhagic event or dementia per patient registry after three and five years respectively from end of trial. | From baseline to five years. |
Blood pressure | Change in both systolic and diastolic blood pressure (unit mmHg). | From baseline to three months. |
Heart rate | Change in heart rate (unit beats per minute). | From baseline to three months. |
Adverse events | Difference in adverse events between groups. | From baseline to three months. |
Critères d'éligibilité
Âges éligibles
Adulte, Adulte âgé
Âge minimum
50 Years
Sexes éligibles
Tous
- MRI/computed tomography (CT) evidence of small vessel occlusion stroke(s)/lacunar stroke(s) (involving ≤2 cm in the acute phase and ≤1.5cm in the late phase) and/or confluent deep white matter hyperintensities (≥ grade 2 on Fazekas's scale).
- Clinical evidence of cerebral small vessel disease can be: a) small vessel occlusion stroke (lacunar stroke) syndrome with symptoms lasting > 24 hours, occurring < 5 years ago; OR b) transient ischemic attack (TIA) with symptoms lasting < 24 hours AND with MR-DWI imaging performed acutely showing small vessel occlusion stroke, occurring < 5 years ago; OR c) TIA with symptoms lasting < 24 hours AND no acute MRI-DWI lesion but MRI/CT evidence of CSVD with old small vessel occlusion stroke(s) (involving ≤1.5cm) and/or confluent deep white matter hyperintensities (≥ grade 2 on Fazekas's scale).
- Age ≥ 50 years.
- Known diagnosis of dementia, medically treated dementia, or under investigation for dementia
- Pregnancy or nursing
- Women of childbearing age not taking contraception
- Known cortical infarction (> 1.5 cm maximum diameter)
- Known carotid artery stenosis ≥ 50 % with Doppler ultrasound, CT angiography, or MRI angiography diagnosed within the last five years
- Known carotid or vertebral dissection as a cause of stroke
- Stroke after carotid or heart surgery
- Known hypercoagulable disease
- Systolic BP < 90 and/or diastolic BP < 50
- Known severe renal impairment (eGFR < 30ml/min)
- Known severe hepatic impairment (Child-Pugh > B)
- History of non-arthritic anterior ischemic optic neuropathy
- Concomitant use of PDE5 inhibitors e.g. sildenafil, tadalafil, and vardenafil during trial period
- Patients receiving nicorandil and nitrates e.g. isosorbide mononitrate, isosorbide dinitrate, glyceryl trinitrate
- History of acute myocardial infarction in the last three months before trial intervention
- Body weight > 130kg
- Known cardiac failure (NYHA ≥ II)
- Known persistent or paroxysmal atrial fibrillation/flutter
- History of "sick sinus syndrome" or other supraventricular cardiac conduction conditions such as sinoatrial or atrioventricular block (2nd of 3rd degree)
- Other known cardiogenic cause of stroke
- Contraindication to CO2 challenge, eg severe respiratory disease
- MRI not tolerated or contraindicated
- Known monogenic causes of stroke i.e. CADASIL
- Unable to provide informed consent
- The participant does not wish to be informed about results from the MRI
Christina Kruuse- 🔬Danish Research Centre for Magnetic Resonance
- 🏥Bispebjerg Hospital
- 🏥Rigshospitalet, Denmark
Université de Copenhague224 essais cliniques actifs à explorer- 🧬The Novo Nordic Foundation
- 🏥Nordsjaellands Hospital
Partie responsable de l'essai
Christina Kruuse, Promoteur-Investigateur, MD, Ph.D., DMSc, Professor in Neurology, Herlev Hospital
Aucune donnée de contact disponible
2 Centres de l'essai dans 1 pays
Department of Neurology, Herlev Gentofte Hospital, Herlev, 2730, Denmark
Danish Research Centre for Magnetic Resonance, Hvidovre, 2650, Denmark